Raymond James initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $54 price target The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to overcome the toxicity and bio-distribution shortcomings associated with systemic administration of rapamycin. Qtorin has the potential for a blockbuster launch in microcystic lymphatic malformations, with a second potential blockbuster in cutaneous venous malformations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Innovative QTORIN Platform and Promising Pipeline Drive Buy Rating for Palvella Therapeutics
- Palvella Therapeutics initiated with an Outperform at LifeSci Capital
- Palvella Therapeutics initiated with a Buy at Truist
- Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
- Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential